Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2006 3
2008 1
2010 1
2011 4
2012 3
2013 2
2015 1
2017 1
2018 4
2019 2
2020 3
2021 3
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Tominersen in Adults with Manifest Huntington's Disease.
McColgan P, Thobhani A, Boak L, Schobel SA, Nicotra A, Palermo G, Trundell D, Zhou J, Schlegel V, Sanwald Ducray P, Hawellek DJ, Dorn J, Simillion C, Lindemann M, Wheelock V, Durr A, Anderson KE, Long JD, Wild EJ, Landwehrmeyer GB, Leavitt BR, Tabrizi SJ, Doody R; GENERATION HD1 Investigators. McColgan P, et al. N Engl J Med. 2023 Dec 7;389(23):2203-2205. doi: 10.1056/NEJMc2300400. N Engl J Med. 2023. PMID: 38055260 No abstract available.
An MDS Evidence-Based Review on Treatments for Huntington's Disease.
Ferreira JJ, Rodrigues FB, Duarte GS, Mestre TA, Bachoud-Levi AC, Bentivoglio AR, Burgunder JM, Cardoso F, Claassen DO, Landwehrmeyer GB, Kulisevsky J, Nirenberg MJ, Rosser A, Roth J, Seppi K, Slawek J, Furr-Stimming E, Tabrizi SJ, Walker FO, Vandenberghe W, Costa J, Sampaio C. Ferreira JJ, et al. Mov Disord. 2022 Jan;37(1):25-35. doi: 10.1002/mds.28855. Epub 2021 Nov 29. Mov Disord. 2022. PMID: 34842303 Review.
BACKGROUND: Huntington's disease (HD) is a rare neurodegenerative disorder with protean clinical manifestations. ...
BACKGROUND: Huntington's disease (HD) is a rare neurodegenerative disorder with protean clinical manifestations. ...
Symptomatic treatment options for Huntington's disease (guidelines of the German Neurological Society).
Saft C, Burgunder JM, Dose M, Jung HH, Katzenschlager R, Priller J, Nguyen HP, Reetz K, Reilmann R, Seppi K, Landwehrmeyer GB. Saft C, et al. Neurol Res Pract. 2023 Nov 16;5(1):61. doi: 10.1186/s42466-023-00285-1. Neurol Res Pract. 2023. PMID: 37968732 Free PMC article.
INTRODUCTION: Ameliorating symptoms and signs of Huntington's disease (HD) is essential to care but can be challenging and hard to achieve. ...
INTRODUCTION: Ameliorating symptoms and signs of Huntington's disease (HD) is essential to care but can be challenging and hard to ac …
Seminar on choreas.
Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Cardoso F, et al. Lancet Neurol. 2006 Jul;5(7):589-602. doi: 10.1016/S1474-4422(06)70494-X. Lancet Neurol. 2006. PMID: 16781989 Review.
Diagnostic work-up can be straightforward in patients with a positive family history of Huntington's disease or acute-onset hemichorea in patients with lacunar stroke, but it can be a challenging and complex task in rare autoimmune or genetic choreas. Principles of managem …
Diagnostic work-up can be straightforward in patients with a positive family history of Huntington's disease or acute-onset hemichore …
Tit for Tat: Costly Punishment in Manifest Huntington's Disease.
Heim B, Peball M, Saft C, von Hein SM, Piater JM, Ellmerer P, Seppi K, Djamshidian-Tehrani A. Heim B, et al. Neurodegener Dis. 2021;21(3-4):74-78. doi: 10.1159/000520303. Epub 2021 Oct 27. Neurodegener Dis. 2021. PMID: 34706364 Free article.
OBJECTIVE: We aimed to investigate costly punishment in patients with Huntington's disease (HD). BACKGROUND: HD is an autosomal dominant neurodegenerative disease with motor, cognitive, and psychiatric symptoms. ...
OBJECTIVE: We aimed to investigate costly punishment in patients with Huntington's disease (HD). BACKGROUND: HD is an autosomal domin …
Cannabinoids for Treatment of Dystonia in Huntington's Disease.
Saft C, von Hein SM, Lücke T, Thiels C, Peball M, Djamshidian A, Heim B, Seppi K. Saft C, et al. J Huntingtons Dis. 2018;7(2):167-173. doi: 10.3233/JHD-170283. J Huntingtons Dis. 2018. PMID: 29562549
BACKGROUND: Motor symptoms in Huntington's disease (HD) are heterogeneous with dystonia being described as a symptom with a very high prevalence not only in juvenile cases. ...In addition we review the current literature concerning the use of cannabinoids in HD. METHOD: Th …
BACKGROUND: Motor symptoms in Huntington's disease (HD) are heterogeneous with dystonia being described as a symptom with a very high …
Hospital Admissions of Huntington's Disease Patients in a Huntington's Disease Centre Between 2011 and 2016: A Retrospective Analysis.
Peball M, Heim B, Ellmerer P, Frank F, Busin N, Galffy M, Djamshidian A, Seppi K. Peball M, et al. Mov Disord Clin Pract. 2022 May 5;9(5):628-636. doi: 10.1002/mdc3.13459. eCollection 2022 Jul. Mov Disord Clin Pract. 2022. PMID: 35844271 Free PMC article.
METHODS: We reviewed all medical records of patients with an established diagnosis of Huntington's Disease and hospital admissions between 2011 and 2016 in our local hospital-based database. ...CONCLUSIONS: Worsening of motor and psychiatric symptoms associated with Hun
METHODS: We reviewed all medical records of patients with an established diagnosis of Huntington's Disease and hospital admissions be …
International Guidelines for the Treatment of Huntington's Disease.
Bachoud-Lévi AC, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, Craufurd D, Reilmann R, De Michele G, Rae D, Squitieri F, Seppi K, Perrine C, Scherer-Gagou C, Audrey O, Verny C, Burgunder JM. Bachoud-Lévi AC, et al. Front Neurol. 2019 Jul 3;10:710. doi: 10.3389/fneur.2019.00710. eCollection 2019. Front Neurol. 2019. PMID: 31333565 Free PMC article.
The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommendations for everyday clinical practice for treatment of Huntington's disease (HD). ...
The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommenda …
33 results